Niki BioSolutions, Inc.
NIKI Healthcare Biotechnology
Niki BioSolutions, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $431,400.00, down 66.7% from fiscal 2022.
Follow NIKI
Niki BioSolutions, Inc. (NIKI) Altman Z-score
Niki BioSolutions, Inc.'s Altman Z-score for fiscal 2023 is −5.03, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2023 | −5.03 | 1.47 |
| FY2022 | −6.50 | (7.75) |
| FY2021 | 1.25 | (4.70) |
| FY2020 | 5.94 | (19.95) |
| FY2019 | 25.90 | 6.13 |
| FY2018 | 19.77 | — |
How fiscal 2023’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.02 | — | 0.02 | |
| Retained earnings / total assets | (3.30) | — | −4.62 | |
| EBIT / total assets | (0.52) | — | −1.71 | |
| Market value of equity / total liabilities | 2.11 | — | 1.26 | |
| Sales / total assets | 0.02 | — | 0.02 | |
| Altman Z-score | Distress zone | −5.03 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −11.06 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| NIKI Niki BioSolutions, Inc. | −5.0× |
| CLGN CollPlant Biotechnologies Ltd. Sponsored ADR compare | −16.9× |
| XCUR Exicure, Inc. compare | −18.3× |
| SYBX Synlogic, Inc. compare | −35.8× |
| AIM AIM ImmunoTech Inc. compare | −114× |
| BCLI Brainstorm Cell Therapeutics Inc. compare | — |
| FBLG FibroBiologics Inc. compare | — |
| SKYE Skye Bioscience, Inc. compare | — |
| ACXP Acurx Pharmaceuticals, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets